Kyowa Kirin Co., Ltd. (KYKOF)
KYKOF Stock Price Chart
Explore Kyowa Kirin Co., Ltd. interactive price chart. Choose custom timeframes to analyze KYKOF price movements and trends.
KYKOF Company Profile
Discover essential business fundamentals and corporate details for Kyowa Kirin Co., Ltd. (KYKOF) to support your stock research and investment decisions.
Sector
Healthcare
Industry
Drug Manufacturers - General
IPO Date
17 Aug 2012
Employees
5.67K
Website
https://www.kyowakirin.comCEO
Masashi Miyamoto
Description
Kyowa Kirin Co., Ltd. manufactures and markets pharmaceuticals that focuses on the therapeutic areas of oncology, nephrology, central nervous system, and immunology worldwide. Its products include ABSTRAL, a sublingual formulation of fentanyl used for the management of episodes of breakthrough pain experienced by cancer patients; ALLELOCK, an antihistamine agent for patients with various types of allergies; CONIEL, a calcium channel blocker for hypertension and angina pectoris; Crysvita, a recombinant human monoclonal IgG1 antibody against the phosphaturic hormone fibroblast growth factor 23; ESPO, a glycoprotein and human erythropoietin; NESP, an erythropoiesis stimulating agent; and GRAN, a human colony-stimulating factor. The company also develops G-LASTA/Peglasta/Neulasta for chemotherapy-induced febrile neutropenia; LEUNASE for acute lymphoblastic leukemia; LUMICEF, a biological treatment for moderate to severe plaque psoriasis; Moventig, a mu-opioid receptor antagonist for the treatment of opioid induced constipation; Nouriast/ Nourianz, an adenosine receptor antagonist for Parkinson's disease; and ORKEDIA, an oral calcimimetics agent. In addition, it offers PecFent, a nasally administrated spray; POTELIGEO, a humanized monoclonal antibody for CC chemokine receptor 4; REGPARA for the treatment of secondary hyperparathyroidism; Romiplate/Nplate, a genetically recombinant protein for platelet production of thrombopoietin receptors; and SANCUSO for the treatment of nausea and vomiting. Kyowa Kirin Co., Ltd. has an agreement with Amgen Inc. to jointly develop and commercialize KHK4083, a Phase 3-ready anti-OX40 fully human monoclonal antibody for the treatment of atopic dermatitis. The company was formerly known as Kyowa Hakko Kirin Co., Ltd. and changed its name to Kyowa Kirin Co., Ltd. in June 2019. The company was incorporated in 1949 and is headquartered in Tokyo, Japan. Kyowa Kirin Co., Ltd. is a subsidiary of Kirin Holdings Company, Limited.
KYKOF Financial Timeline
Browse a chronological timeline of Kyowa Kirin Co., Ltd. corporate events including earnings releases, dividend announcements, and stock splits.
Upcoming earnings on 29 Apr 2026
Upcoming earnings on 4 Feb 2026
Upcoming earnings on 30 Oct 2025
Revenue estimate is $827.29M.
Earnings released on 31 Jul 2025
EPS came in at $0.13 falling short of the estimated $0.22 by -39.07%, while revenue for the quarter reached $873.82M , beating expectations by +4.54%.
Earnings released on 5 May 2025
EPS came in at $0.08 falling short of the estimated $0.15 by -44.98%, while revenue for the quarter reached $698.10M , missing expectations by -20.03%.
Dividend declared on 6 Feb 2025
A dividend of $0.20 per share was announced, adjusted to $0.20. The dividend will be paid on 1 Mar 2026.
Dividend declared on 6 Feb 2025
A dividend of $0.21 per share was announced, adjusted to $0.21. The dividend was paid on 1 Sept 2025.
Earnings released on 5 Feb 2025
EPS came in at $0.05 surpassing the estimated $0.00 by +3.64K%, while revenue for the quarter reached $844.35M , beating expectations by +7.30%.
Dividend declared on 27 Dec 2024
A dividend of $0.18 per share was announced, adjusted to $0.18. The dividend was paid on 21 Mar 2025.
Earnings released on 31 Oct 2024
EPS came in at $0.23 falling short of the estimated $0.23 by -3.62%, while revenue for the quarter reached $903.19M , beating expectations by +2.21%.
Earnings released on 1 Aug 2024
EPS came in at $0.30 surpassing the estimated $0.19 by +55.46%, while revenue for the quarter reached $793.22M , beating expectations by +9.06%.
Earnings released on 7 May 2024
EPS came in at $0.17 falling short of the estimated $0.21 by -18.28%, while revenue for the quarter reached $695.91M , missing expectations by -0.38%.
Earnings released on 7 Feb 2024
EPS came in at $0.35 falling short of the estimated $0.51 by -32.31%, while revenue for the quarter reached $973.45M , beating expectations by +14.88%.
Dividend declared on 7 Feb 2024
A dividend of $0.18 per share was announced, adjusted to $0.18. The dividend was paid on 21 Mar 2025.
Dividend declared on 7 Feb 2024
A dividend of $0.18 per share was announced, adjusted to $0.18. The dividend was paid on 2 Sept 2024.
Earnings released on 30 Sept 2023
EPS came in at $0.40 falling short of the estimated $0.41 by -3.12%, while revenue for the quarter reached $714.96M , missing expectations by -3.87%.
Earnings released on 30 Jun 2023
EPS came in at $0.11 falling short of the estimated $0.18 by -36.66%, while revenue for the quarter reached $731.22M , missing expectations by -3.95%.
Earnings released on 31 Mar 2023
EPS came in at $0.18 falling short of the estimated $0.21 by -15.72%, while revenue for the quarter reached $705.91M , missing expectations by -6.89%.
Earnings released on 7 Feb 2023
EPS came in at $0.06 falling short of the estimated $0.21 by -70.08%, while revenue for the quarter reached $883.46M , beating expectations by +60.03%.
Dividend declared on 7 Feb 2023
A dividend of $0.21 per share was announced, adjusted to $0.19. The dividend was paid on 25 Mar 2024.
Dividend declared on 7 Feb 2023
A dividend of $0.19 per share was announced, adjusted to $0.19. The dividend was paid on 1 Sept 2023.
Earnings released on 4 Nov 2022
EPS came in at $0.18 falling short of the estimated $0.18 by -2.93%, while revenue for the quarter reached $681.25M , missing expectations by -4.15%.
Earnings released on 4 Aug 2022
EPS came in at $0.26 surpassing the estimated $0.19 by +35.82%, while revenue for the quarter reached $717.47M , beating expectations by +1.72%.
Earnings released on 10 May 2022
EPS came in at $0.23 surpassing the estimated $0.16 by +41.42%, while revenue for the quarter reached $717.63M , missing expectations by -3.28%.
Earnings released on 7 Feb 2022
EPS came in at $0.31 surpassing the estimated $0.18 by +71.46%, while revenue for the quarter reached $854.44M , missing expectations by -0.55%.
Dividend declared on 7 Feb 2022
A dividend of $0.20 per share was announced, adjusted to $0.18. The dividend was paid on 27 Mar 2023.
Dividend declared on 7 Feb 2022
A dividend of $0.18 per share was announced, adjusted to $0.18. The dividend was paid on 1 Sept 2022.
Earnings released on 1 Nov 2021
EPS came in at $0.13 falling short of the estimated $0.23 by -44.99%, while revenue for the quarter reached $798.55M .
Earnings released on 3 Aug 2021
EPS came in at $0.21 falling short of the estimated $0.23 by -10.63%, while revenue for the quarter reached $754.96M .
Earnings released on 6 May 2021
EPS came in at $0.22 falling short of the estimated $0.25 by -11.23%, while revenue for the quarter reached $733.83M .
Earnings released on 4 Feb 2021
EPS came in at $0.17 falling short of the estimated $0.20 by -17.38%, while revenue for the quarter reached $816.28M .
Dividend declared on 4 Feb 2021
A dividend of $0.20 per share was announced, adjusted to $0.20. The dividend was paid on 28 Mar 2022.
Dividend declared on 4 Feb 2021
A dividend of $0.21 per share was announced, adjusted to $0.21. The dividend was paid on 1 Sept 2021.
Earnings released on 30 Oct 2020
EPS came in at $0.17 falling short of the estimated $0.19 by -8.87%, while revenue for the quarter reached $721.73M .
Dividend declared on 5 Feb 2020
A dividend of $0.21 per share was announced, adjusted to $0.21. The dividend was paid on 25 Mar 2021.
KYKOF Stock Performance
Access detailed KYKOF performance analysis with candlestick charts, real‑time intraday data and historical financial metrics for comprehensive insights.
Explore Related Stocks
Compare companies within the same sector by viewing performance, key financials, and market trends. Select a symbol to access the full profile.